ArticleJournal of molecular histology2025
SARS-CoV-2 causes gastric damage: structural and ultrastructural evaluation.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infects the gastrointestinal tract; however, its effects on the stomach and underlying mechanisms remain unknown. The presence of ACE2 (angiotensin-converting enzyme 2) receptors in the gastric mucosa suggests that the stomach is vulnerable to infection. This study is the first to examine SARS-CoV-2's impact on distinct cell types within gastric tissue, alongside the involvement of protective mechanisms and cell death pathways. K18-hACE2 transgenic mice (n = 20) were divided into control and SARS-CoV-2 groups, and their gastric tissues were analyzed on day 8 post-infection to represent the acute phase. Epithelial degeneration, hemorrhage, glandular cell damage, inflammatory infiltration, and muscle injury were assessed and scored, alongside apoptosis, pyroptosis, necroptosis, and Galectin-3 expression levels. Ultrastructural changes were identified using transmission electron microscopy. The SARS-CoV-2 group exhibited significant epithelial desquamation, extensive tissue damage (P < 0.0001), diminished mucin content, elevated apoptosis (P = 0.0279) and pyroptosis (P = 0.0265), and reduced Galectin-3 expression (P = 0.0211). Parietal cells showed pronounced structural damage and strong SARS-CoV-2 positivity, highlighting their susceptibility and potential role in gastric dysfunction during infection. Virus-like particles (70-110 nm) were observed within cells and in vesicles. Enteroendocrine cells displayed heightened activity. SARS-CoV-2 infection caused significant damage to gastric epithelial and parietal cells through inflammatory, apoptotic, and pyroptotic mechanisms, likely exacerbated by reduced Galectin-3 expression and consequent impairment of gastric protection. This damage may amplify susceptibility to secondary infections, such as H. pylori, and could contribute to clinical symptoms such as nausea, dyspepsia, and unexplained gastric complaints observed in SARS-CoV-2 cases.
Indexed as
Identifiers
40542875What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.